Sachin V. Suryavanshi

Verified @gmail.com

Sachin V. Suryavanshi


               Download Compact PDF  
https://researchid.co/suryavanshi43
14

Scopus Publications

826

Scholar Citations

13

Scholar h-index

14

Scholar i10-index

Scopus Publications

  • Abrogation of cardiomyopathy in diabetic rats by escin–possible role of NF-κβ and MCP-1
    Sachin V. Suryavanshi, Yogesh A. Kulkarni
    Archives of Physiology and Biochemistry, 2024
    OBJECTIVE Diabetic cardiomyopathy is one of the most common complications of diabetes. Escin may significantly inhibit myocardial damage through its NF-κβ inhibitory, antidiabetic, neuroprotective, and potent anti-inflammatory activity. Hence, the study was carried out to evaluate the effect of escin in diabetic cardiomyopathy. METHODS Diabetes induction was done in rats with streptozotocin. After six weeks of induction, diabetic animals were administered with escin (5, 10, and 20 mg/kg) for the next four weeks. RESULTS Escin prevented the progression of abnormalities in the biochemical, hemodynamic parameters and electrocardiogram. Escin also prevented the progression of abnormality in the oxidative stress parameters. The expression of NF-κβ and MCP-1 was significantly reduced with escin treatment. Furthermore, escin also prevented damage to myocardial cells and reduced collagen deposition in the cardiomyocytes. CONCLUSION Escin prevented the progression of cardiomyopathy in diabetic rats. Hence escin can be an alternative option for the management of diabetic cardiomyopathy.
  • Triphala churna ameliorates retinopathy in diabetic rats
    Sachin V. Suryavanshi, Kalyani Barve, Sachin V. Utpat, Yogesh A. Kulkarni
    Biomedicine and Pharmacotherapy, 2022
    Diabetic retinopathy is one of the most prevalent complications of diabetes affecting a large number of people worldwide. Triphala churna - an Ayurvedic formulation consisting of powder of three fruits, Emblica officinalis, Terminalia bellirica and Terminalia chebula has potent antioxidant and anti-diabetic properties. Hence, the study was designed to evaluate the effect of Triphala churna in diabetic retinopathy. Diabetes was induced in rats with streptozotocin (55 mg/kg, i.p.). After four weeks of induction, animals were treated with Triphala churna powder mixed in a vehicle at a dose of 250, 500, and 1000 mg/kg for the next four weeks. At the end of the study, plasma glucose, lactate dehydrogenase levels were determined. Sorbitol dehydrogenase, aldose reductase, and oxidative stress parameters were determined in lens tissues. Electroretinography was carried out. Histopathology study of the retina was studied at the end of the study. Triphala churna significantly reduced plasma glucose and lactate dehydrogenase levels. Triphala significantly reduced sorbitol dehydrogenase, aldose reductase, and oxidative stress in lens tissues. Furthermore, Triphala significantly increased 'a' wave and 'b' wave amplitude with a reduction in the latencies. The retinal thickness was significantly reduced in Triphala-treated animals. From the results, it can be concluded that Triphala churna delays the progression of retinopathy in diabetic rats.
  • Toxicity of escin-triterpene saponins from Aesculus
    Sachin V. Suryavanshi, Yogesh A. Kulkarni
    Toxicological and Environmental Chemistry, 2022
    Escin has effects on inflammation and is useful for the treatment of varicose veins and cancer. Scientific reports on the toxicity profile of escin are not available. Oral acute toxicity in rats was studied. At 2000 mg/kg, escin was lethal to all animals while at 300 mg/kg no signs of toxicity, changes in body weight, food and water consumption were observed within 14 days. A 28-days oral toxicity study was performed at daily doses of 5, 10, and 20 mg/kg of escin. Bodyweight, food, and water intake were not altered. There were neither significant changes in biochemical and hematological parameters nor any histopathological changes in organs after treatment with escin for 28 days. Escin was found to be safe at all selected dose levels in a repeated dose toxicity study.
  • Triphala Churna—A Traditional Formulation in Ayurveda Mitigates Diabetic Neuropathy in Rats
    Sachin V. Suryavanshi, Kalyani Barve, Veeranjaneyulu Addepalli, Sachin V. Utpat, Yogesh A. Kulkarni
    Frontiers in Pharmacology, 2021
    Neuropathy is a common complication of diabetes affecting a large number of people worldwide. Triphala churna is a formulation mentioned in Ayurveda-a traditional system of medicine. It is a simple powder formulation consisting of powders of three fruits, Emblica officinalis L., Terminalia bellirica (Gaertn.) Roxb. and Terminalia chebula Retz. Individual components of Triphala churna have anti-diabetic and antioxidant activities. Hence, this study was designed to evaluate the effect of Triphala churna on diabetic neuropathy. Diabetes was induced with streptozotocin (STZ, 55 mg/kg, i. p.) in rats. Animals were grouped and treated orally with Triphala churna at a dose of 250, 500, and 1,000 mg/kg after 6 weeks of diabetes induction for the next 4 weeks. At the end of study, parameters such as body weight, plasma glucose level, motor nerve conduction velocity were determined. The effect of Triphala churna on thermal hyperalgesia, mechanical hyperalgesia, and mechanical allodynia was also determined at the end of study. The plasma cytokine levels like TGF-β1, TNF-α, and IL-1β were determined by ELISA assay. Histopathology study of the sciatic nerve was studied. Western blotting was performed to study the expression of neuronal growth factor.Treatment with Triphala churna showed a significant reduction in plasma glucose and a significant rise in body weight. Triphala treatment significantly increased the motor nerve conduction velocity and decreased the thermal and mechanical hyperalgesia, as well as mechanical allodynia. The treatment significantly inhibited levels of circulatory cytokines like TGF-β1, TNF-α, and IL-1β. Histopathology study confirmed the neuroprotective effect of Triphala churna. The expression of NGF was significantly increased in sciatic nerves after treatment with Triphala churna. From the results, it can be concluded that Triphala churna delays the progression of neuropathy in diabetic rats.
  • Attenuation of Cardiac Autonomic Neuropathy by Escin in Diabetic Rats
    Sachin V. Suryavanshi, Yogesh A. Kulkarni
    Pharmacology, 2021
    Cardiac autonomic neuropathy (CAN) is a least diagnosed complication of diabetes. Inflammation and oxidative stress play a crucial role in the pathophysiology of cardiomyopathy and neuropathy. Escin has anti-inflammatory activity and antioxidant activity. Hence, the present study was designed to evaluate the effect of escin in the management of CAN. Diabetes was induced in Sprague Dawley rats with streptozotocin (STZ). Diabetic animals were randomized in different groups after 6 weeks. Animals in the diabetic control group received no treatment, while animals in other groups received escin at dose 5, 10, and 20 mg/kg for 4 weeks. One group was kept as normal control. Various parameters like basic hemodynamic parameters, heart rate variability (HRV), oxidative stress parameters, and matrix metalloproteinase 9 (MMP-9) were assessed at the end of study. Escin significantly normalized hemodynamic parameters and HRV as compared to diabetic animals. Escin significantly reduced the malondialdehyde level and significantly increased reduced glutathione, catalase and superoxide dismutase levels in diabetic animals. Escin treatment significantly reduced plasma MMP-9 level in diabetic rats. The improvement in the studied parameters was found mainly with administration of higher doses of escin (10 and 20 mg/kg). The escin treatment mitigates CAN in diabetic rats. The results of study indicate that escin can be useful option for management of CAN.
  • Combination of naringenin and lisinopril ameliorates nephropathy in type-1 diabetic rats
    Yogesh A. Kulkarni, Sachin V. Suryavanshi
    Endocrine Metabolic and Immune Disorders Drug Targets, 2021
    Background: Diabetes is a metabolic disorder affecting a large percentage of the population worldwide. The chronic hyperglycemic condition leads to the generation of advanced glycation end products, reactive oxygen species and inflammatory cytokines, which worsen the functioning of the kidney. Clinical management of diabetic nephropathy is difficult as it requires a multi-focused approach. Hence, a combination of lisinopril a drug used in clinical practice for nephropathy, and naringenin, a flavonoid reported to have a significant effect in nephropathy, may show additive or synergistic effect with less side effects. Objective: The objective of the present study was to evaluate the effect of a combination of lisinopril with naringenin in diabetic nephropathy. Methods: Diabetes was induced in male Sprague Dawley rats by streptozotocin (55 mg/kg, i.p.). After four weeks of diabetes induction animals were treated with naringenin alone and a combination of Lisinopril and naringenin for the next four weeks. At the end of the study, various urine and biochemical parameters were evaluated. Oxidative stress parameters like malondialdehyde, reduced glutathione; catalase and superoxide dismutase for kidney tissues were estimated and histopathology studies of kidneys were carried out. Results: The combination of lisinopril (10 mg/kg) and naringenin (25 and 50 mg/kg) treatment showed significant improvement in the biochemical and urine parameters. Combination treatment also attenuated renal oxidative stress and renal damage as observed in histopathological studies. Conclusion: Treatment with a combination of lisinopril and naringenin showed a promising effect on diabetic nephropathy in rats.
  • Potential of Renin-Angiotensin-Aldosterone System Modulations in Diabetic Kidney Disease: Old Players to New Hope!
    Vajir Malek, Sachin V. Suryavanshi, Nisha Sharma, Yogesh A. Kulkarni, Shrikant R. Mulay, Anil Bhanudas Gaikwad
    Reviews of Physiology Biochemistry and Pharmacology, 2021
    Due to a tragic increase in the incidences of diabetes globally, diabetic kidney disease (DKD) has emerged as one of the leading causes of end-stage renal diseases (ESRD). Hyperglycaemia-mediated overactivation of the renin-angiotensin-aldosterone system (RAAS) is key to the development and progression of DKD. Consequently, RAAS inhibition by angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) is the first-line therapy for the clinical management of DKD. However, numerous clinical and preclinical evidences suggested that RAAS inhibition can only halt the progression of the DKD to a certain extent, and they are inadequate to cure DKD completely. Recent studies have improved understanding of the complexity of the RAAS. It consists of two counter-regulatory arms, the deleterious pressor arm (ACE/angiotensin II/AT1 receptor axis) and the beneficial depressor arm (ACE2/angiotensin-(1-7)/Mas receptor axis). These advances have paved the way for the development of new therapies targeting the RAAS for better treatment of DKD. In this review, we aimed to summarise the involvement of the depressor arm of the RAAS in DKD. Moreover, in modern drug discovery and development, an advance approach is the bispecific therapeutics, targeting two independent signalling pathways. Here, we discuss available reports of these bispecific drugs involving the RAAS as well as propose potential treatments based on neurohormonal balance as credible therapeutic strategies for DKD.
  • Sodium copper chlorophyllin attenuates adenine-induced chronic kidney disease via suppression of TGF-beta and inflammatory cytokines
    Sachin V. Suryavanshi, Milind Gharpure, Yogesh A. Kulkarni
    Naunyn Schmiedeberg S Archives of Pharmacology, 2020
    The present study was designed to evaluate the effect of sodium copper chlorophyllin (SCC) in adenine-induced chronic kidney disease (CKD). CKD was induced in male Wistar rats by feeding 0.3% w/w adenine diet for 28 days. After induction, animals were treated with sodium copper chlorophyllin at dose 2.7, 5.4, and 10.8 mg/kg for the next 28 days. The biochemical and urines parameters like creatinine, blood urea nitrogen (BUN), albumin, total protein creatinine clearance, urea clearance, and glomerular filtration rate were assessed on days 0, 14, and 28. Plasma TGF-β1, COX-2, and IL-6 levels were assessed. Various oxidative stress parameters and TGF-β1 expression were determined in the kidney. Histopathology of the kidney was studied with different stains. Sodium copper chlorophyllin-treated animals showed a significant reduction in urine output and relative kidney weight. The treatment with sodium copper chlorophyllin significantly improved kidney function by normalizing biochemical and urine parameters. Treatment with SCC significantly reduced circulatory inflammatory mediators—TGF-β1, COX-2, and IL-6. Additionally, the treatment also significantly reduced oxidative stress and TGF-β1 expression in kidney tissues. Histopathology studies showed inhibition in the kidney damage due to the treatment of SCC. The sodium copper chlorophyllin treatment attenuated adenine-induced chronic kidney disease in rats.
  • Triphala Ameliorates Nephropathy via Inhibition of TGF-β1 and Oxidative Stress in Diabetic Rats
    Sachin V. Suryavanshi, Mayuresh S. Garud, Kalyani Barve, Veeranjaneyulu Addepalli, Sachin V. Utpat, Yogesh A. Kulkarni
    Pharmacology, 2020
    <b><i>Introduction:</i></b> Advanced glycation end products, oxidative stress, and TGF-β expression play a crucial role in pathophysiology of diabetic nephropathy. Inhibition of oxidative stress and TGF-β expression by natural traditional medicines may give an economic and safe alternative treatment option. Triphala churna, a traditional medicine, has been proved to have potent antioxidant activity, and individual components of it have shown significant antidiabetic activity. Hence, the present study was designed to study the effect of Triphala churna in diabetic nephropathy in rats. <b><i>Methods:</i></b> Diabetes was induced in rats by administration of streptozotocin (55 mg/kg i.p.). Four weeks after induction of diabetes, the animals were treated with Triphala churna at the doses of 250, 500, and 1,000 mg/kg for next 4 weeks. Various biochemical and urine parameters such as glucose, creatinine, blood urea nitrogen (BUN), total protein, and albumin were assessed at the end of study. Creatinine clearance, BUN clearance, and glomerular filtration rate were determined. Oxidative stress parameters such as malondialdehyde, catalase, reduced glutathione, and superoxide dismutase were determined in kidney tissues. TGF-β1 expression was measured with ELISA, immunohistochemistry, and western blot techniques. Histopathology study was carried out with haemotoxylin and eosin, periodic acid-Schiff, and Masson’s trichrome staining to determine histological changes. <b><i>Results:</i></b> Treatment with Triphala churna significantly improved urine parameters. Triphala churna treatment also improved plasma proteins, albumin, creatinine, and BUN levels. The oxidative stress was reduced in the kidney with the treatment of Triphala churna. Histopathological studies revealed that Triphala churna reduced kidney damage. Immunohistochemistry, ELISA, and western blotting study revealed that treatment with Triphala decreased the expression of TGF-β in kidney tissues. <b><i>Conclusion:</i></b> From the results, it can be concluded that Triphala churna has a significant nephroprotective effect because of its capability of inhibiting oxidative stress and TGF-β in diabetes.
  • Escin alleviates peripheral neuropathy in streptozotocin induced diabetes in rats
    Sachin V. Suryavanshi, Yogesh A. Kulkarni
    Life Sciences, 2020
  • Catechin attenuates diabetic autonomic neuropathy in streptozotocin induced diabetic rats
    Veeranjaneyulu Addepalli, Sachin V. Suryavanshi
    Biomedicine and Pharmacotherapy, 2018
  • Acute toxicity study and anti-nociceptive activity of Bauhinia acuminata Linn. leaf extracts in experimental animal models
    Ashika V. Padgaonkar, Sachin V. Suryavanshi, Vaishali Y. Londhe, Yogesh A. Kulkarni
    Biomedicine and Pharmacotherapy, 2018
  • NF-κβ: A potential target in the management of vascular complications of diabetes
    Sachin V. Suryavanshi, Yogesh A. Kulkarni
    Frontiers in Pharmacology, 2017
  • Capsicum: A Natural Pain Modulator
    Y.A. Kulkarni, S.V. Suryavanshi, S.T. Auti, A.B. Gaikwad
    Nutritional Modulators of Pain in the Aging Population, 2017

RECENT SCHOLAR PUBLICATIONS

  • Escin Prolongs Progression of Retinopathy in Diabetic Rats (Abstract ID: 171938)
    Y Kulkarni, SV Suryavanshi
    The Journal of Pharmacology and Experimental Therapeutics 392 (3) , 2025
    2025
  • Abrogation of cardiomyopathy in diabetic rats by escin–possible role of NF-κβ and MCP-1
    SV Suryavanshi, YA Kulkarni
    Archives of Physiology and Biochemistry 130 (1), 49-55 , 2024
    2024
    Citations: 6
  • Triphala churna ameliorates retinopathy in diabetic rats
    SV Suryavanshi, K Barve, SV Utpat, YA Kulkarni
    Biomedicine & Pharmacotherapy 148, 112711 , 2022
    2022
    Citations: 21
  • Toxicity of escin-triterpene saponins from Aesculus
    SV Suryavanshi, YA Kulkarni
    Toxicological & Environmental Chemistry 104 (1), 141-148 , 2022
    2022
    Citations: 7
  • Triphala Churna—a traditional formulation in ayurveda mitigates diabetic neuropathy in rats
    SV Suryavanshi, K Barve, V Addepalli, SV Utpat, YA Kulkarni
    Frontiers in pharmacology 12, 662000 , 2021
    2021
    Citations: 34
  • Attenuation of cardiac autonomic neuropathy by escin in diabetic rats
    SV Suryavanshi, YA Kulkarni
    Pharmacology 106 (3-4), 211-217 , 2021
    2021
    Citations: 18
  • Combination of naringenin and lisinopril ameliorates nephropathy in type-1 diabetic rats
    YA Kulkarni, SV Suryavanshi
    Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug … , 2021
    2021
    Citations: 12
  • Sodium copper chlorophyllin attenuates adenine-induced chronic kidney disease via suppression of TGF-beta and inflammatory cytokines
    SV Suryavanshi, M Gharpure, YA Kulkarni
    Naunyn-Schmiedeberg's Archives of Pharmacology 393 (11), 2029-2041 , 2020
    2020
    Citations: 14
  • Potential of renin-angiotensin-aldosterone system modulations in diabetic kidney disease: old players to new hope!
    V Malek, SV Suryavanshi, N Sharma, YA Kulkarni, SR Mulay, AB Gaikwad
    Reviews of physiology, biochemistry and pharmacology, 31-71 , 2020
    2020
    Citations: 41
  • Escin alleviates peripheral neuropathy in streptozotocin induced diabetes in rats
    SV Suryavanshi, YA Kulkarni
    Life sciences 254, 117777 , 2020
    2020
    Citations: 35
  • Triphala Ameliorates Nephropathy via Inhibition of TGF-β1 and Oxidative Stress in Diabetic Rats
    SV Suryavanshi, MS Garud, K Barve, V Addepalli, SV Utpat, YA Kulkarni
    Pharmacology, 1-11 , 2020
    2020
    Citations: 26
  • Molecular Targets of Angiogenesis and Future Potential of Anti-angiogensis Therapy in Multiple Sclerosis
    MJ Oza, SV Suryavanshi, MS Garud, ST Auti, AP Laddha, YA Kulkarni
    Anti-Angiogenesis Drug Discovery and Development: Volume 4, 137-161 , 2019
    2019
  • Catechin attenuates diabetic autonomic neuropathy in streptozotocin induced diabetic rats
    V Addepalli, SV Suryavanshi
    Biomedicine & Pharmacotherapy 108, 1517-1523 , 2018
    2018
    Citations: 96
  • Catechin attenuates diabetic autonomic neuropathy in streptozotocin induced diabetic rats.
    VA Veeranjaneyulu Addepalli, SV Suryavanshi
    2018
  • Attenuation of diabetic nephropathy by Triphala-a traditional formulation from Ayurveda
    YA Kulkarni, SV Suryavanshi, MS Garud, KH Barve, A Veeranjaneyulu, ...
    Proceedings for Annual Meeting of The Japanese Pharmacological Society … , 2018
    2018
  • Acute toxicity study and anti-nociceptive activity of Bauhinia acuminata Linn. Leaf extracts in experimental animal models
    AV Padgaonkar, SV Suryavanshi, VY Londhe, YA Kulkarni
    Biomedicine & Pharmacotherapy 97, 60-66 , 2018
    2018
    Citations: 26
  • NF-κβ: a potential target in the management of vascular complications of diabetes
    SV Suryavanshi, YA Kulkarni
    Frontiers in pharmacology 8, 798 , 2017
    2017
    Citations: 432
  • NF-Κβ: a potential target in the management of vascular complications of diabetes, Front. Pharmacol. 8 (2017) 798
    SV Suryavanshi, YA Kulkarni
    2017
    Citations: 6
  • Role of artificial intelligence in health care
    S Mishra, A Takke, S Auti, S Suryavanshi, M Oza
    BioChemistry: An Indian Journal 11 (5), 1-14 , 2017
    2017
    Citations: 22
  • Capsicum: a natural pain modulator
    YA Kulkarni, SV Suryavanshi, ST Auti, AB Gaikwad
    Nutritional modulators of pain in the aging population, 107-119 , 2017
    2017
    Citations: 17

MOST CITED SCHOLAR PUBLICATIONS

  • NF-κβ: a potential target in the management of vascular complications of diabetes
    SV Suryavanshi, YA Kulkarni
    Frontiers in pharmacology 8, 798 , 2017
    2017
    Citations: 432
  • Catechin attenuates diabetic autonomic neuropathy in streptozotocin induced diabetic rats
    V Addepalli, SV Suryavanshi
    Biomedicine & Pharmacotherapy 108, 1517-1523 , 2018
    2018
    Citations: 96
  • Potential of renin-angiotensin-aldosterone system modulations in diabetic kidney disease: old players to new hope!
    V Malek, SV Suryavanshi, N Sharma, YA Kulkarni, SR Mulay, AB Gaikwad
    Reviews of physiology, biochemistry and pharmacology, 31-71 , 2020
    2020
    Citations: 41
  • Escin alleviates peripheral neuropathy in streptozotocin induced diabetes in rats
    SV Suryavanshi, YA Kulkarni
    Life sciences 254, 117777 , 2020
    2020
    Citations: 35
  • Triphala Churna—a traditional formulation in ayurveda mitigates diabetic neuropathy in rats
    SV Suryavanshi, K Barve, V Addepalli, SV Utpat, YA Kulkarni
    Frontiers in pharmacology 12, 662000 , 2021
    2021
    Citations: 34
  • Triphala Ameliorates Nephropathy via Inhibition of TGF-β1 and Oxidative Stress in Diabetic Rats
    SV Suryavanshi, MS Garud, K Barve, V Addepalli, SV Utpat, YA Kulkarni
    Pharmacology, 1-11 , 2020
    2020
    Citations: 26
  • Acute toxicity study and anti-nociceptive activity of Bauhinia acuminata Linn. Leaf extracts in experimental animal models
    AV Padgaonkar, SV Suryavanshi, VY Londhe, YA Kulkarni
    Biomedicine & Pharmacotherapy 97, 60-66 , 2018
    2018
    Citations: 26
  • Role of artificial intelligence in health care
    S Mishra, A Takke, S Auti, S Suryavanshi, M Oza
    BioChemistry: An Indian Journal 11 (5), 1-14 , 2017
    2017
    Citations: 22
  • Triphala churna ameliorates retinopathy in diabetic rats
    SV Suryavanshi, K Barve, SV Utpat, YA Kulkarni
    Biomedicine & Pharmacotherapy 148, 112711 , 2022
    2022
    Citations: 21
  • Attenuation of cardiac autonomic neuropathy by escin in diabetic rats
    SV Suryavanshi, YA Kulkarni
    Pharmacology 106 (3-4), 211-217 , 2021
    2021
    Citations: 18
  • Capsicum: a natural pain modulator
    YA Kulkarni, SV Suryavanshi, ST Auti, AB Gaikwad
    Nutritional modulators of pain in the aging population, 107-119 , 2017
    2017
    Citations: 17
  • Sodium copper chlorophyllin attenuates adenine-induced chronic kidney disease via suppression of TGF-beta and inflammatory cytokines
    SV Suryavanshi, M Gharpure, YA Kulkarni
    Naunyn-Schmiedeberg's Archives of Pharmacology 393 (11), 2029-2041 , 2020
    2020
    Citations: 14
  • Pharmacognostic and phytochemical evaluation of Strobilanthes sessilis nees. Leaves
    SVS VS Shende, SD Jadhav, NH Aloorkar, AS Kulkarni
    International Journal of Pharmacognosy 2 (6), 310-314 , 2015
    2015
    Citations: 13
  • Combination of naringenin and lisinopril ameliorates nephropathy in type-1 diabetic rats
    YA Kulkarni, SV Suryavanshi
    Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug … , 2021
    2021
    Citations: 12
  • Toxicity of escin-triterpene saponins from Aesculus
    SV Suryavanshi, YA Kulkarni
    Toxicological & Environmental Chemistry 104 (1), 141-148 , 2022
    2022
    Citations: 7
  • Abrogation of cardiomyopathy in diabetic rats by escin–possible role of NF-κβ and MCP-1
    SV Suryavanshi, YA Kulkarni
    Archives of Physiology and Biochemistry 130 (1), 49-55 , 2024
    2024
    Citations: 6
  • NF-Κβ: a potential target in the management of vascular complications of diabetes, Front. Pharmacol. 8 (2017) 798
    SV Suryavanshi, YA Kulkarni
    2017
    Citations: 6
  • Escin Prolongs Progression of Retinopathy in Diabetic Rats (Abstract ID: 171938)
    Y Kulkarni, SV Suryavanshi
    The Journal of Pharmacology and Experimental Therapeutics 392 (3) , 2025
    2025
  • Molecular Targets of Angiogenesis and Future Potential of Anti-angiogensis Therapy in Multiple Sclerosis
    MJ Oza, SV Suryavanshi, MS Garud, ST Auti, AP Laddha, YA Kulkarni
    Anti-Angiogenesis Drug Discovery and Development: Volume 4, 137-161 , 2019
    2019
  • Catechin attenuates diabetic autonomic neuropathy in streptozotocin induced diabetic rats.
    VA Veeranjaneyulu Addepalli, SV Suryavanshi
    2018